The Patent Finder

Adaptive Biologix, Inc.

Also on record
Records under this name other than patents Adaptive Biologix, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.

Showing 1 to 6 of 6 · Back to Adaptive Biologix, Inc.

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 11,191,780Extracellular matrix compositions for the treatment of cancer or immunological diseases
Lapsed on the fee record
Ended Dec 7, 2025 · USPTO record
Lapsed on the fee recordEnded Dec 7, 2025USPTO record
US 9,506,038Extracellular matrix compositions for the treatment of cancer
Lapsed on the fee record
Ended Nov 29, 2024 · USPTO record
Lapsed on the fee recordEnded Nov 29, 2024USPTO record
US 10,675,303Extracellular matrix compositions for the treatment of cancer
Lapsed on the fee record
Ended Jun 9, 2024 · USPTO record
Lapsed on the fee recordEnded Jun 9, 2024USPTO record
US 9,034,312Extracellular matrix compositions for the treatment of cancer
Lapsed on the fee record
Ended May 19, 2023 · USPTO record
Lapsed on the fee recordEnded May 19, 2023USPTO record
US 10,143,708Extracellular matrix compositions for the treatment of cancer
Formerly held
Lapsed on the fee record
Ended Dec 4, 2022 · USPTO record
Lapsed on the fee recordEnded Dec 4, 2022USPTO record
US 8,852,637Extracellular matrix compositions for the treatment of cancer
Lapsed on the fee record
Ended Oct 7, 2022 · USPTO record
Lapsed on the fee recordEnded Oct 7, 2022USPTO record
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited